Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00228969 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
A Phase 2 study of Refractory Epilepsy, sponsored by SK Life Science.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00228969: Completed Phase 2 study of Refractory Epilepsy, sponsored by SK Life Science.
NCT00228969 is a Phase 2 study of Refractory Epilepsy that has completed, run by SK Life Science. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00228969, a Phase 2 study of Refractory Epilepsy, has completed, sponsored by SK Life Science.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive
Conditions Studied
Interventions
- DRUG RWJ-333369
Study Locations (20)
Alabama
- - Birmingham
- - Huntsville
- - Mobile
- - Northport
California
- - Irvine
- - Northridge
- - Sacramento
Kentucky
- - Lexington
- - Louisville
Minnesota
- - Golden Valley
- - Saint Paul
Arizona
- - Phoenix
Arkansas
- - Little Rock
Colorado
- - Fort Collins
Delaware
- - Wilmington
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-02 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00228969 record still lists
NCT00228969 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Refractory Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which RWJ-333369 is the first listed.
NCT00228969 names 20 study sites across 13 states, led by Alabama, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00228969 about?
NCT00228969 is a clinical study titled "Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy". The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive
What is the current status of trial NCT00228969?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-02. Estimated completion is 2006-05.
What conditions does trial NCT00228969 study?
This clinical trial studies the following conditions: Refractory Epilepsy.
What interventions are being tested in trial NCT00228969?
The interventions under investigation include: RWJ-333369 (DRUG).
Who is sponsoring clinical trial NCT00228969?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00228969 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
RECRUITING · Phase 2
-
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
RECRUITING · NA
-
Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application
RECRUITING · NA
-
Optimal Stimulation Parameters to Disrupt Epileptiform Activity
RECRUITING · NA
-
Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia